Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

497 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prevalence and factors associated with symptom persistence: A prospective study of 429 mild COVID-19 outpatients.
Faycal A, Ndoadoumgue AL, Sellem B, Blanc C, Dudoit Y, Schneider L, Tubiana R, Valantin MA, Seang S, Palich R, Bleibtreu A, Monsel G, Godefroy N, Itani O, Paccoud O, Pourcher V, Caumes E, Ktorza N, Chermak A, Abdi B, Assoumou L, Katlama C; COVIDOM-19 PSL research group. Faycal A, et al. Among authors: blanc c. Infect Dis Now. 2022 Mar;52(2):75-81. doi: 10.1016/j.idnow.2021.11.003. Epub 2021 Nov 17. Infect Dis Now. 2022. PMID: 34800742 Free PMC article.
Long-term follow-up of HIV-infected patients on dolutegravir monotherapy.
Tebano G, Soulié C, Schneider L, Blanc C, Agher R, Seang S, Valantin MA, Palich R, Tubiana R, Peytavin G, Marcelin AG, Assoumou L, Katlama C. Tebano G, et al. Among authors: blanc c. J Antimicrob Chemother. 2020 Mar 1;75(3):675-680. doi: 10.1093/jac/dkz478. J Antimicrob Chemother. 2020. PMID: 31800056
Multimorbidity in Elderly Persons According to the Year of Diagnosis of Human Immunodeficiency Virus Infection: A Cross-sectional Dat'AIDS Cohort Study.
Demontès M, Eymard Duvernay S, Allavena C, Jovelin T, Reynes J, Hentzien M, Ravaux I, Delobel P, Bregigeon S, Rey D, Ferry T, Gagneux-Brunon A, Robineau O, Pugliese P, Duvivier C, Cabié A, Chirouze C, Jacomet C, Lamaury I, Merrien D, Hoen B, Hocqueloux L, Cheret A, Katlama C, Arvieux C, Krolak-Salmon P, Makinson A; Dat’AIDS Study Group. Demontès M, et al. Clin Infect Dis. 2020 Dec 31;71(11):2880-2888. doi: 10.1093/cid/ciz1171. Clin Infect Dis. 2020. PMID: 31813982
Rapid plasma viral suppression in naive HIV-infected patients with high CD4 cells and low viraemia initiating a dual nucleoside reverse transcriptase inhibitor strategy: a proof-of-concept study.
Seang S, Fourati S, Keita Y, Blanc C, Tubiana R, Schneider L, Valantin MA, Caby F, Calin R, Lambert-Niclot S, Marcelin AG, Calvez V, Costagliola D, Katlama C. Seang S, et al. Among authors: blanc c. J Antimicrob Chemother. 2014 Dec;69(12):3356-9. doi: 10.1093/jac/dku265. Epub 2014 Jul 22. J Antimicrob Chemother. 2014. PMID: 25056835
Dolutegravir as monotherapy in HIV-1-infected individuals with suppressed HIV viraemia.
Katlama C, Soulié C, Caby F, Denis A, Blanc C, Schneider L, Valantin MA, Tubiana R, Kirstetter M, Valdenassi E, Nguyen T, Peytavin G, Calvez V, Marcelin AG. Katlama C, et al. Among authors: blanc c. J Antimicrob Chemother. 2016 Sep;71(9):2646-50. doi: 10.1093/jac/dkw186. Epub 2016 Jun 10. J Antimicrob Chemother. 2016. PMID: 27287235
Once-daily etravirine/raltegravir (400/800 mg q24h) dual therapy maintains viral suppression over 48 weeks in HIV-infected patients switching from a twice-daily etravirine/raltegravir (200/400 mg q12h) regimen.
Palich R, Allavena C, Peytavin G, Soulie C, Tubiana R, Weiss L, Montoya Ferrer A, Duvivier C, Bouchaud O, Bottero J, Durand A, Lê MP, Marcelin AG, Dudoit Y, Assoumou L, Katlama C; ETRAL QD study group. Palich R, et al. J Antimicrob Chemother. 2021 Jan 19;76(2):477-481. doi: 10.1093/jac/dkaa423. J Antimicrob Chemother. 2021. PMID: 33099638 Clinical Trial.
497 results